Clark Estates Inc. NY Lowers Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Clark Estates Inc. NY lessened its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 17.3% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 39,100 shares of the medical equipment provider’s stock after selling 8,200 shares during the period. Lantheus accounts for about 0.8% of Clark Estates Inc. NY’s holdings, making the stock its 18th biggest position. Clark Estates Inc. NY’s holdings in Lantheus were worth $4,291,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. GAMMA Investing LLC boosted its holdings in shares of Lantheus by 184.1% in the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 208 shares in the last quarter. Signaturefd LLC boosted its stake in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 92 shares in the last quarter. Nkcfo LLC acquired a new position in Lantheus during the second quarter worth $47,000. UMB Bank n.a. lifted its holdings in Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after acquiring an additional 126 shares during the period. Finally, Kathleen S. Wright Associates Inc. acquired a new position in shares of Lantheus during the 3rd quarter worth $51,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Trading Down 1.6 %

NASDAQ:LNTH opened at $89.53 on Wednesday. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89. The firm has a market capitalization of $6.23 billion, a price-to-earnings ratio of 14.90 and a beta of 0.51. The firm’s fifty day simple moving average is $102.80 and its 200 day simple moving average is $97.04.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Redburn Atlantic initiated coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price on the stock. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Truist Financial restated a “buy” rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Finally, JMP Securities reduced their target price on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $122.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.